PLUS THERAPEUTICS Inc. Common Stock (PSTV)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses I can understand, with durable competitive advantages and honest financials. Plus Therapeutics is a clinical-stage cancer company with 28 employees, betting on radiotherapeutics like rhenium obisbemeda. There is no commercial engine yet, so the moat is unproven; intellectual property and regulatory progress may matter, but they are not the same as a proven earnings moat. Financial health is poor. Trailing free cash flow is -$23.5 million, a -49.4% FCF yield against a $47.7 million market cap. Return on capital employed is -73.82%. The Piotroski F-Score is 1/9 and Altman Z-Score is -49.45, both warning signs. Debt is low at D/E 0.06, which helps, but low debt does not offset cash burn. As of the 2026-08-07 close, the stock was $3.84, with a 52-week range of $2.90 to $19.00. FairStock calculations show P/E 0.18, P/B 2.21, Graham Number $19.07, and a 79.87% margin of safety. Those value signals are alluring, but Graham would ask whether the earnings are real and repeatable; the negative operating cash flow says caution. The FairStock score is 16/100, and Lynch category is none because there are only 0 years of filed results—need 3. Growth is not demonstrated; no revenue growth figure is provided, and the business remains pre-commercial. This is a speculative biotechnology story, not a compounding bargain. I would need evidence of commercial progress and a path to positive cash flow before trusting the cheap-looking ratios.

In plain English: Plus Therapeutics is a very small cancer-drug developer with 28 employees. The company is not yet profitable and is burning cash, so the business looks financially weak. At $3.84, the stock is far below its 52-week high of $19.00, and while some accounting measures make it look cheap, the cash losses and poor financial scores suggest the price is speculative rather than a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-08-07 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer